Kerrisdale Advisers, LLC Liquidia Corp Transaction History

Kerrisdale Advisers, LLC

  • $284 Million
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$6.27 - $8.15 $503,142 - $654,004
80,246 New
80,246 $508,000
Q1 2023

May 15, 2023
SELL
$5.72 - $7.91 $952,654 - $1.32 Million
-166,548 Reduced 83.47%
32,992 $227,000
Q4 2022

Feb 14, 2023
BUY
$4.68 - $6.54 $933,847 - $1.3 Million
199,540 New
199,540 $1.27 Million

Others Institutions Holding LQDA

# of Institutions
162
Shares Held
36M
Call Options Held
1.79M
Put Options Held
380K
View Full List

About Liquidia Corp

LQDA Quotes by TradingView
  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $709M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Kerrisdale Advisers, LLC Portfolio

Follow Kerrisdale Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kerrisdale Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kerrisdale Advisers, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email